MONTREAL, June 25, 2013 /CNW Telbec/ - Boeckh Investments Inc., a
private company based in Montreal, today issued the following letter on
behalf of a group of independent shareholders of Bioniche Life Sciences
Inc. (TSX: BNC) (ASX: BNC):
Dear fellow shareholders:
I am writing this letter on behalf of a group of independent
shareholders of Bioniche Life Sciences Inc. Our own shareholdings,
including affiliates, come to over 4 million shares. We have confirmed
support for the views expressed in this letter from other independent
shareholders owning or controlling over 12 million shares of Bioniche.
Together, this group owns or controls over 16 million shares which
represent approximately 15% of the outstanding shares of Bioniche.
The group wishes to inform the shareholder community that it supports
the plan approved by the Board of Directors of Bioniche to sell the
animal health business, subject to shareholder approval. At the right
price, Bioniche should be well-positioned to use the excess sale
proceeds to exploit the global commercialization of Urocidin, which we
believe has good potential.
Until the planned shareholder vote on November 5, 2013, Bioniche needs
time to conduct a sound sale process without distraction.
This press release is not and does not constitute a solicitation of
Boeckh Investments Inc.
SOURCE: Boeckh Investments Inc.
For further information:
For more information or comments, please send emails to email@example.com